Differential effects of atypical and typical antipsychotic drugs on N-methyl-D-aspartate- and electrically evoked responses in the pyramidal cells of the rat medial prefrontal cortex

Synapse

Volumn 48, Issue 2, 2003, Pages 66-79

  Ninan, Ipe ^a,b   Jardemark, Kent E ^a   Wang, Rex Y ^a  

^a STONY BROOK UNIVERSITY   (United States)

^b NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

Author keywords

Antipsychotics; Clozapine; Medial prefrontal cortex; NMDA receptors; Pyramidal cells; Schizophrenia

Indexed keywords

6 CYANO 7 NITRO 2,3 QUINOXALINEDIONE; ALPHA (2,3 DIMETHOXYPHENYL) 1 [2 (4 FLUOROPHENYL)ETHYL] 4 PIPERIDINEMETHANOL; ALPHA AMINO 3 HYDROXY 5 METHYL 4 ISOXAZOLEPROPIONIC ACID; ATYPICAL ANTIPSYCHOTIC AGENT; BICUCULLINE METHIODIDE; CHLORPROMAZINE; CLOZAPINE; HALOPERIDOL; LOXAPINE; N METHYL DEXTRO ASPARTIC ACID; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; UNCLASSIFIED DRUG; Y 931;

ANIMAL TISSUE; ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; ELECTROSTIMULATION; EVOKED RESPONSE; NEUROTRANSMISSION; NONHUMAN; PREFRONTAL CORTEX; PRIORITY JOURNAL; PYRAMIDAL NERVE CELL; RAT; SCHIZOPHRENIA; SYNAPSE;

ACTION POTENTIALS; ANIMALS; ANTIPSYCHOTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTRIC STIMULATION; N-METHYLASPARTATE; PREFRONTAL CORTEX; PYRAMIDAL CELLS; RATS; RATS, SPRAGUE-DAWLEY;

EID: 0037401685     PISSN: 08874476     EISSN: None     Source Type: Journal    
DOI: 10.1002/syn.10189     Document Type: Article

References (54)

1. 2A receptors, increases EPSCs in layer V pyramidal cells of prefrontal cortex by an asynchronous mode of glutamate release. Brain Res 825:161-171.
2. Akbarian S, Sucher NJ, Bradley D, Tafazzoli A, Trinh D, Hetrick WP, Potkin SG, Sandman CA, Bunney Jr WE, Jones EG. 1996. Selective alterations in gene expression for NMDA receptor subunits in prefrontal cortex of schizophrenics. J Neurosci 16:19-30.
3. Arnt J, Skarsfeldt T. 1998. Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. Neuropsychopharmacology 18:63-101.
4. Arvanov VL, Wang RY. 1997. NMDA-induced response in pyramidal neurons of the rat medial prefrontal cortex slices consists of NMDA and non-NMDA components. Brain Res 768:361-364.
5. 2A receptor antagonist and a potential antipsychotic drug, facilitates N-methyl-D-aspartate-receptor mediated neurotransmission in the rat medial prefrontal cortical neurons in vitro. Neuropsychopharmacology 18: 197-209.
6. Arvanov VL, Liang X, Schwartz J, Grossman S, Wang RY. 1997. Clozapine and haloperidol modulate N-methyl-D-aspartate- and non-N-methyl-D-aspartate receptor-mediated neurotransmission in rat prefrontal cortical neurons in vitro. J Pharmacol Exp Ther 283:226-234.
7. 2A receptor agonist DOB on NMDA-evoked responses in pyramidal neurons of the rat medial prefrontal cortex. Eur J Neurosci 11:2917-2934.
8. Bymaster F, Perry KW, Nelson DL, Wong DT, Rasmussen K, Moore NA, Calligaro DO. 1999. Olanzapine: a basic science update. Br J Psychiatry 174:36-40.
9. Carlsson ML. 1998. Hypothesis: is infantile autism a hypoglutamatergic disorder? Relevance of glutamate-serotonin interactions for pharmacotherapy. J Neural Transm 105:525-535.
10. 1 and NMDA receptors mediates acute clozapine potentiation of glutamate EP-SPs in rat prefrontal cortex. J Neurophysiol 87:2324-2336.
11. Connors BW, Gutnick MJ. 1990. Intrinsic firing patterns of diverse neocortical neurons. Trends Pharmacol Sci 13:99-104.
12. Daly DA, Moghaddam B. 1993. Actions of clozapine and haloperidol on the extracellular levels of excitatory amino acids in the prefrontal cortex and striatum of conscious rats. Neurosci Lett 152:61- 64.
13. Davis PC, Wong J, Gefvert O. 1999. Analysis and pharmacokinetics of quetiapine and two metabolites in human plasma using reversed-phase HPLC with ultraviolet and electrochemical detection. J Pharm Biomed Anal 20:271-282.
14. Deutsch SI, Mastropaolo J, Schwartz BL, Rosse RB, Morihisa JM. 1989. A "glutamatergic hypothesis" of schizophrenia. Rationale for pharmacotherapy with glycine. Clin Neuropharmacol 12:1-13.
15. Dracheva S, Marras SA, Elhakem SL, Kramer FR, Davis KL, Haroutunian V. 2001. N-methyl-D-aspartic acid receptor expression in the dorsolateral prefrontal cortex of elderly patients with schizophrenia. Am J Psychiatry 158:1400-1410.
16. Finkel AS, Redman SJ. 1985. Optimal voltage clamping with single microelectrodes. In: Smith TG, Lecar A, Redman SJ, Gage PW, editors. Voltage and patch clamping with microelectrodes. Baltimore: Williams & Wilkins. p 95-120.
17. Halliwell JV, Adams PR. 1982. Voltage-clamp analysis of muscarinic excitation in hippocampal neurons. Brain Res 250:71-92.
18. Harrison PJ. 1999. The neuropathology of schizophrenia. A critical review of the data and their interpretation. Brain 122:593-624.
19. 1A receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release. J Neurochem 76:1521-1531.
20. Ishimaru M, Kurumaji A, Toru M. 1994. Increases in strychnineinsensitive glycine binding sites in cerebral cortex of chronic schizophrenics: evidence for glutamate hypothesis. Biol Psychiatry 35: 84-95.
21. Jardemark KE, Ai J, Ninan I, Wang RY. 2001. Biphasic modulation of NMDA-induced responses in pyramidal cells of the medial prefrontal cortex by Y-931, a potential atypical antipsychotic drug. Synapse 41:294-300.
22. Jardemark KE, Ninan I, Liang X, Wang RY. 2003. Protein kinase C is involved in clozapine's facilitation of N-methyl-D-aspartate- and electrically evoked responses in pyramidal cells of the medial prefrontal cortex. Neuroscience (in press).
23. Jenkins AJ, Sarconi KM, Raaf HN. 1998. Determination of olanzapine in a postmortem case. J Anal Toxicol 22:605-609.
24. 2A antagonist with a favorable CNS safety profile. J Pharmacol Exp Ther 277:968-981.
25. Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD, Heninger GR, Bowers Jr MB, Charney DS. 1994. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 51:199-214.
26. Kullmann DM, Asztely F. 1998. Extrasynaptic glutamate spillover in the hippocampus: evidence and implications. Trends Neurosci 21: 8-14.
27. Liang X, Jardemark KE, Wang RY. 1999. Facilitation of the N-methyl-D-aspartate responses in pyramidal cells of the medial prefrontal cortex by clozapine: role of protein kinase C. Soc Neurosci Abstr 25:2048.
28. Malhotra AK, Pinals DA, Weingartner H, Sirocco K, Missar CD, Pickar D, Breier A. 1996. NMDA receptor function and human cognition: the effects of ketamine in healthy volunteers. Neuropsychopharmacology 14:301-307.
29. Malhotra AK, Adler CM, Kennison SD, Elman I, Pickar D, Breier A. 1997. Clozapine blunts N-methyl-D-aspartate antagonist-induced psychosis: a study with ketamine. Biol Psychiatry 42:664-668.
30. Malone RP, Maislin G, Choudhury MS, Gifford C, Delaney MA. 2002. Risperidone treatment in children and adolescents with autism: short- and long-term safety and effectiveness. J Am Acad Child Adolesc Psychiatry 41:140-147.
31. McCormick DA, Connors BW, Lighthall JW, Prince DA. 1985. Comparative electrophysiology of pyramidal and sparsely spiny neurons of the neocortex. J Neurophysiol 54:782-806.
32. 2 pKi values. J Pharmacol Exp Ther 251:238-246.
33. Mohn AR, Gainetdinov RR, Caron MG, Koller BH. 1999. Mice with reduced NMDA receptor expression display behaviors related to schizophrenia. Cell 98:427-436.
34. Murphy BL, Arnsten AF, Goldman-Rakic PS, Roth RH. 1996. Increased dopamine turnover in the prefrontal cortex impairs spatial working memory performance in rats and monkeys. Proc Natl Acad Sci USA 93:1325-1329.
35. Ninan I, Jardemark KE, Liang X, Wang RY. 2003. Calcium/calmodulin-dependent kinase II is involved in the facilitating effect of clozapine on NMDA- and electrically evoked responses in the medial prefrontal cortical pyramidal cells. Synapse 47:285-294.
36. 1 pyramidal neurons: mediation by arachidonic acid and its metabolites. J Neurosci 13:2033-2049.
37. 5 receptor activation selectively enhances sustained synaptic inputs to layer V prefrontal cortex neurons. Proc Natl Acad Sci USA 98:301-306.
38. Sigman M, Dissanayake C, Arbelle S, Ruskin E. 1997. Cognition and emotion in children and adolescent with autism. In: Cohen DJ, Volkmar FR, editors. Handbook of autism and pervasive developmental disorders. New York: John Wiley & Sons. p 248-265.
39. 1 receptor/protein kinase A/dopamine- and cAMP-regulated phosphoprotein (Mr 32 kDa)/protein phosphatase-1 pathway regulates dephosphorylation of the NMDA receptor. J Neurosci 18: 10297-10303.
40. Spina E, Avenoso A, Facciola G, Scordo MG, Ancione M, Madia AG, Ventimiglia A, Perucca E. 2000. Relationship between plasma concentrations of clozapine and norclozapine and therapeutic response in patients with schizophrenia resistant to conventional neuroleptics. Psychopharmacology (Berl) 148:83-89.
41. Spina E, Avenoso A, Facciola G, Salemi M, Scordo MG, Ancione M, Madia AG, Perucca E. 2001. Relationship between plasma risperidone and 9-hydroxyrisperidone concentrations and clinical response in patients with schizophrenia. Psychopharmacology (Berl) 153: 238-243.
42. Tanaka E, North A. 1993. Actions of 5-HT on neurons of rat cingulated cortex. J Neurophysiol 69:1749-1757.
43. Tarazi FI, Floriji J, Creese I. 1996. Regulation of ionotropic glutamate receptors following subchronic and chronic treatment with typical and atypical antipsychotics. Psychopharmacology 128:371-379.
44. Tokunaga H, Kudo K, Imamura T, Jitsufuchi N, Ohtsuka Y, Ikeda N. 1997. Plasma concentrations of antipsychotic drugs in psychiatric inpatients. Nippon Hoigaku Zasshi 51:417-422.
45. 2 receptors of normal human brain in vitro. Eur J Pharmacol 143:279-282.
46. Wang J, O'Donnell P. 2001. D. dopamine receptors potentiate NMDA-mediated excitability increase in layer V prefrontal cortical pyramidal neurons. Cereb Cortex 11:452-462.
47. Wang RY, Liang X, Jardemark KE, Arvanov V. 2000. Facilitation of NMDA transmission by olanzapine. In: Tran PV, Bymaster F, Tye N, Herrera J, Breier A, Tollefson G, editors. Olanzapine (Zyprexa) - a novel antipsychotic. Baltimore: Williams & Wilkins. p 114-131.
48. Westerink BH, de Boer P, de Vries JB, Kruse CG, Long SK. 1998. Antipsychotic drugs induce similar effects on the release of dopamine and noradrenaline in the medial prefrontal cortex of the rat brain. Eur J Pharmacol 361:27-33.
49. 1 receptors in prefrontal cortex. Nature 376:572-575.
50. Yamamoto BK, Pehek EA, Meltzer HY. 1994. Brain region effects of clozapine on amino acid and monoamine transmission. J Clin Psychiatry 55:8-14.
51. Youngren KD, Inglis FM, Pivirotto PJ, Jedema HP, Bradberry CW, Goldman-Rakic PS, Roth RH, Moghaddam B. 1999. Clozapine preferentially increases dopamine release in the rhesus monkey prefrontal cortex compared with caudate nucleus. Neuropsychopharmacology 20:403-412.
52. 1 dopamine receptors in the rodent prefrontal cortex impairs spatial working memory performance. J Neurosci 17: 8528-8535.
53. Zheng P, Zhang XX, Bunney BS, Shi WX. 1999. Opposite modulation of cortical N-methyl-D-aspartate receptor-mediated responses by low and high concentrations of dopamine. Neuroscience 91:527-535.
54. Zilles K. 1985. The cortex of the rat. Berlin/Heidelberg: Springer.